Regentatlantic Capital LLC Reduces Stock Holdings in PerkinElmer, Inc. (NYSE:PKI)

Regentatlantic Capital LLC decreased its holdings in PerkinElmer, Inc. (NYSE:PKI) by 5.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,286 shares of the medical research company’s stock after selling 205 shares during the quarter. Regentatlantic Capital LLC’s holdings in PerkinElmer were worth $317,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in PKI. Quadrant Capital Group LLC purchased a new position in PerkinElmer during the first quarter valued at $25,000. Financial Gravity Wealth Inc. purchased a new position in PerkinElmer during the first quarter valued at $52,000. Signaturefd LLC lifted its position in PerkinElmer by 171.5% during the first quarter. Signaturefd LLC now owns 809 shares of the medical research company’s stock valued at $78,000 after buying an additional 511 shares during the period. Hilton Capital Management LLC purchased a new position in PerkinElmer during the first quarter valued at $82,000. Finally, South Dakota Investment Council purchased a new position in PerkinElmer during the first quarter valued at $87,000. 95.99% of the stock is owned by institutional investors.

Shares of NYSE:PKI traded down $2.22 on Monday, hitting $82.38. 14,237 shares of the company traded hands, compared to its average volume of 699,038. PerkinElmer, Inc. has a 52 week low of $71.83 and a 52 week high of $103.00. The company has a current ratio of 1.82, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The business has a 50 day moving average price of $94.67. The company has a market capitalization of $9.38 billion, a P/E ratio of 22.78, a PEG ratio of 1.50 and a beta of 1.25.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings results on Monday, July 29th. The medical research company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.01). PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. The company had revenue of $722.50 million for the quarter, compared to the consensus estimate of $729.10 million. During the same quarter in the previous year, the business earned $0.91 earnings per share. PerkinElmer’s revenue was up 2.7% compared to the same quarter last year. On average, equities analysts anticipate that PerkinElmer, Inc. will post 4.04 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, October 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.34%. PerkinElmer’s payout ratio is presently 7.76%.

Several equities analysts have commented on the company. UBS Group raised their price objective on PerkinElmer from $99.00 to $101.00 and gave the company a “neutral” rating in a research report on Tuesday, July 30th. Royal Bank of Canada reissued a “hold” rating and set a $41.00 price objective on shares of PerkinElmer in a research report on Friday, May 3rd. Wolfe Research assumed coverage on PerkinElmer in a research report on Thursday, May 30th. They set a “peer perform” rating for the company. Goldman Sachs Group raised PerkinElmer from a “neutral” rating to a “buy” rating and set a $115.00 price objective for the company in a research report on Tuesday, April 9th. Finally, Wood & Company reissued an “average” rating and set a $49.00 price objective on shares of PerkinElmer in a research report on Friday, July 19th. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $78.58.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Story: Do closed-end mutual funds pay dividends?

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.